AstraZeneca plc 21.7% Potential Upside Indicated by Deutsche Bank

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 6900 GBX on its stock. This indicates the analyst now believes there is a potential upside of 21.7% from the opening price of 5669 GBX. Over the last 30 and 90 trading days the company share price has decreased 596 points and increased 120 points respectively. The 52 week high for the share price is currently at 6540 GBX while the year low share price is currently 5110 GBX.

AstraZeneca plc has a 50 day moving average of 6,217.04 GBX and a 200 day moving average of 5,997.38. There are currently 1,966,155,724 shares in issue with the average daily volume traded being 2,985,522. Market capitalisation for LON:AZN is £74,770,273,944 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.

      Search

      Search